These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34101795)

  • 21. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
    Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
    Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
    Behrens S; Rattinger GB; Schwartz S; Matyi J; Sanders C; DeBerard MS; Lyketsos CG; Tschanz JT
    Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain.
    Lopez-Bastida J; Serrano-Aguilar P; Perestelo-Perez L; Oliva-Moreno J
    Neurology; 2006 Dec; 67(12):2186-91. PubMed ID: 17190942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How relevant are social costs in economic evaluations? The case of Alzheimer's disease.
    Peña-Longobardo LM; Rodríguez-Sánchez B; Oliva-Moreno J; Aranda-Reneo I; López-Bastida J
    Eur J Health Econ; 2019 Nov; 20(8):1207-1236. PubMed ID: 31342208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost of dementia in Switzerland.
    Kraft E; Marti M; Werner S; Sommer H
    Swiss Med Wkly; 2010; 140():w13093. PubMed ID: 22250014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study.
    Belger M; Haro JM; Reed C; Happich M; Kahle-Wrobleski K; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
    BMC Med Res Methodol; 2016 Jul; 16():83. PubMed ID: 27430559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
    Getsios D; Blume S; Ishak KJ; Maclaine GD
    Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The economic impact of moderate stage Alzheimer's disease in Italy: evidence from the UP-TECH randomized trial.
    Chiatti C; Furneri G; Rimland JM; Demma F; Bonfranceschi F; Cassetta L; Masera F; Cherubini A; Corsonello A; Lattanzio F;
    Int Psychogeriatr; 2015 Sep; 27(9):1563-72. PubMed ID: 25874654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the Severity of Alzheimer's Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan.
    Ashizawa T; Igarashi A; Sakata Y; Azuma M; Fujimoto K; Kobayashi T; Takase Y; Ikeda S
    J Alzheimers Dis; 2021; 81(1):367-374. PubMed ID: 33780368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients.
    Beeri MS; Werner P; Davidson M; Noy S
    Int J Geriatr Psychiatry; 2002 May; 17(5):403-8. PubMed ID: 11994927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic Analysis of Formal Care, Informal Care, and Productivity Losses in Primary Care Patients who Screened Positive for Dementia in Germany.
    Michalowsky B; Thyrian JR; Eichler T; Hertel J; Wucherer D; Flessa S; Hoffmann W
    J Alzheimers Dis; 2016; 50(1):47-59. PubMed ID: 26639964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2021 Mar; 17(3):327-406. PubMed ID: 33756057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.
    Reese JP; Hessmann P; Seeberg G; Henkel D; Hirzmann P; Rieke J; Baum E; Dannhoff F; Müller MJ; Jessen F; Geldsetzer MB; Dodel R
    J Alzheimers Dis; 2011; 27(4):723-36. PubMed ID: 21876256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost of Alzheimer's disease in managed care: a cross-sectional study.
    Leon J; Neumann PJ
    Am J Manag Care; 1999 Jul; 5(7):867-77. PubMed ID: 10557408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study.
    Moore MJ; Zhu CW; Clipp EC
    J Gerontol B Psychol Sci Soc Sci; 2001 Jul; 56(4):S219-28. PubMed ID: 11445614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
    Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
    J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The economic and social burden of dementia diseases in Germany-A meta-analysis].
    Michalowsky B; Kaczynski A; Hoffmann W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Aug; 62(8):981-992. PubMed ID: 31297549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost of dementia in Europe: a review of the evidence, and methodological considerations.
    Jönsson L; Wimo A
    Pharmacoeconomics; 2009; 27(5):391-403. PubMed ID: 19586077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the relationship between Alzheimer's disease severity and longitudinal costs.
    Rapp T; Andrieu S; Molinier L; Grand A; Cantet C; Mullins CD; Vellas B
    Value Health; 2012 May; 15(3):412-9. PubMed ID: 22583450
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.